Dr. Ashwin Singh Parihar sits down with Dr. Louise Emmett to discuss how post-therapy Lutetium-177 PSMA SPECT/CT may help predict overall survival in patients with metastatic castration resistant prostate cancer and shape future treatment decisions. Drawing from the ENZA-p trial run by ANZUP cancer trials group, they explore quantitative imaging, treatment response assessment, adaptive dosing strategies, and the growing role of theranostics in precision oncology.   177Lu-PSMA-617 SPECT/CT for Early Prediction of Overall Survival in Participants with Metastatic Castration-Resistant Prostate Cancer. Ayati et al. Radiology 2026; 319(1):e252672.